A significant partnership has been formed to address the growing challenge of dementia care in Nigeria. A United Kingdom-based MedTech firm, Glow Therapeutics, has entered into a Memorandum of Understanding (MoU) with Nigeria's NeuralVillage Healthcare & Technology Ltd. The agreement, announced on December 5, 2025, initiates an exploratory collaboration aimed at delivering targeted support for people living with dementia across the country.
Addressing a Critical National Health Burden
According to a press release from the companies, the collaboration will focus on understanding how Glow Therapeutics' Harmoni Technology can be introduced into Nigeria. The partners plan to utilize community and government pathways for distribution. This strategy is crucial given the scale of the issue. Nigeria is home to more than 1.5 million people living with dementia, with families bearing the overwhelming majority of daily care and support responsibilities.
Japhet Kineze, the Founder and CEO of NeuralVillage, emphasized the urgent need for practical tools. He stated that accessible solutions are desperately required to make life easier in the early and mid-stages after diagnosis. This is particularly vital for individuals and families managing symptoms like Sundowning, a state of confusion occurring in the late afternoon and evening.
Leveraging Nigeria's Healthcare Structure for Impact
The initiative plans to tap directly into Nigeria's existing public health framework. The nation's healthcare system is organized around 36 States and 774 Local Government Areas (LGAs). These LGAs, responsible for primary healthcare delivery, are often the first point of contact for vulnerable households. The partnership views this structure as a natural and effective channel for distributing technology designed to help families manage dementia at home.
NeuralVillage will contribute its deep, on-the-ground insight into Nigeria's public sector landscape. The company brings years of experience in community health, neurological care, and civic engagement. Its understanding of how healthcare decisions flow at the State and LGA level will be central to exploring how Harmoni can reach those who need it most.
Building a Scalable Model for the Future
In the coming months, both organizations will map out regulatory and operational pathways. They will also identify specific LGAs that could form the basis of a pilot program. The ultimate aim is to build a sustainable model that can support families across Nigeria and create a scalable route for accessible dementia support.
Stuart Craig, the Co-founder of Glow Therapeutics, expressed strong confidence in the Nigerian healthcare market. He believes it has the foundation to become a leading environment for neurotechnology companies. His vision is for companies at every stage to use technology to tackle the complex neurological challenges faced by millions of Nigerians.
Japhet Kineze also shared a broader vision, urging the Federal Government to prioritize neurological care. He highlighted the suffering in grassroots communities due to a lack of access to neurotechnology devices and the neglect of many primary healthcare centers. He envisions Nigeria becoming a global hub for Neuroscience Technology.
Both companies have expressed excitement about the new MoU and look forward to sharing further updates as their collaborative work progresses.
